The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

Understanding the differences between colds, flu, and RSV can help in identifying the illness you're dealing with, the ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

In recent weeks, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to dismantle decades of vaccine safety ...

A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

FEV1/FVC was significantly lower in young adults who had severe bronchiolitis during infancy vs those who did not. Severe bronchiolitis during infancy may contribute to irreversible airway obstruction ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...